Intellia Therapeutics, Inc. is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company's CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing. Its portfolio includes CRISPR/Cas9 platform technology, delivery technologies and nucleic acid modifications for human therapeutic use. The Company's CRISPR/Cas9 platform components include the guide ribonucleic acid (RNA) and the Cas9 nuclease (the genetic scissors). It has access to various delivery modalities specific to various in vivo and ex vivo approaches. The Company focuses on engineering ex vivo CRISPR/Cas9 cell therapies for chimeric antigen receptor T cell (CAR-T) and hematopoietic stem cell (HSC) applications. It also focuses on the use of in vivo Lipid Nanoparticle (LNP) delivery technology.